Dr. Peter Hotez expressed concern that canceling mRNA contracts will chill pharmaceutical investment and disrupt research into cancer immunotherapeutics. He revealed that many of these federal contracts were "advanced purchase" agreements, suggesting the financial impact on companies is a primary driver of the current media backlash.
